Wall Street Journal: Some emerging scientific research points to an increased risk for patients taking certain GLP-1s to develop NAION. But the evidence is mixed, and not clear enough to say whether or how the drugs cause the condition, doctors and researchers said.
…Still, some countries have compelled Novo and Eli Lilly to include warnings or information about NAION on the drugs’ labels. There is no such warning in the U.S., though the Food and Drug Administration is investigating the potential link after first identifying a possible connection to NAION in late 2024…